期刊文献+

慢性免疫性血小板减少症患者miR-491-5p表达情况及临床意义 被引量:2

Increasing expression of miR-491-5p in patients with primary immune thrombocytopenia and clinical significance
下载PDF
导出
摘要 目的研究micro-RNA(miR)-491-5p在慢性免疫性血小板减少症(ITP)患者外周血单个核细胞(PBMC)中的表达及临床意义。方法收集滁州市第一人民医院健康体检者38例(健康对照组),慢性ITP患者38例(慢性ITP组),其中治疗后缓解组为26例,未缓解组12例。所有研究对象均采集外周静脉血2mL,分离PBMC,提取细胞总RNA,逆转录合成cDNA,以U6为内参,应用实时荧光定量PCR(RT-PCR)的方法检测miR-491-5p的表达量;采用Pearson相关分析慢性ITP患者miR-491-5p与血小板计数之间的相关性。应用ROC曲线分析miR-491-5p分子标志物的诊断价值。结果慢性ITP组与健康对照组相比,miR-491-5p的表达增高;治疗后与治疗前比较,PBMC的miR-491-5p的表达下降;慢性ITP患者PBMC中miR-491-5p的表达量与血小板计数呈负相关(r=-0.661 2,P<0.05)。慢性ITP患者PBMC的miR-491-5p ROC曲线下面积为0.929 4。结论 miR-491-5p参与慢性ITP的发病过程,有望成为慢性ITP诊断治疗、预后实时监测的标志物。 Objective To investigate the expression of micro-RNA(miR)-491-5p in the peripheral blood mononuclear cells(PBMC)of primary immune thrombocytopenia(ITP)patients,and further to explore its clinical significance.Methods From 2016 to 2018,38 cases of ITP patients and 38 healthy subjects were collected from Chuzhou first people′s hospital,after treatment,there were 26 cases in the remission group and 12 cases in the non-remission group.Peripheral blood were tested,PBMC were separated and total RNA was extracted from the cells,cDNA was synthesized by reverse transcription,U6 used as an internal reference,then the expression of miR-491-5p were tested by real-time fluorescent quantitative PCR(RT-PCR);Pearson correlation analysis was to measure the relation between miR-491-5p and platelet count.Receiver operator characteristic curves were used to confirm the performance of miR-491-5p.Results Compared with the healthy control group,the expression of miR-491-5p increased in PBMC of chronic ITP group.After treatment,the expression of miR-491-5p decreased.The miR-491-5p level in ITP patients was negatively correlated with the platelet counts(r=-0.661 2,P<0.05).The area under curve(AUC)for miR-491-5p in ITP patients was 0.929 4.Conclusion MiR-491-5p is involved in the pathogenesis of ITP,which would be a marker for the diagnosis,treatment and monitoring of ITP in the future.
作者 周艳 钱琤 ZHOU Yan;QIAN Cheng(Department of Clinical Laboratory,Chuzhou First People's Hospital,Chuzhou,Anhui 239000,China;Department of Clinical Laboratory,No.904 Hospital of PLA,Suzhou,Jiangsu 215007,China)
出处 《检验医学与临床》 CAS 2019年第9期1153-1155,共3页 Laboratory Medicine and Clinic
基金 国家自然科学基金资助项目(81701608 81501397 81501398) 中国博士后科学基金资助项目(2017M623440) 军队重点科研基金资助项目(15ZD009)
关键词 miR-491-5p 外周血单个核细胞 慢性免疫性血小板减少症 miR-491-5p peripheral blood mononuclear cells primary immune thrombocytopenia
  • 相关文献

二级参考文献30

  • 1张欣,高清平,王琼玉,王巧玲,张文芳.B淋巴细胞的细胞周期蛋白表达及周期分布在特发性血小板减少性紫癜发病机制中的意义[J].中华血液学杂志,2006,27(9):630-631. 被引量:3
  • 2ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186. 被引量:1
  • 3NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207. 被引量:1
  • 4British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x. 被引量:1
  • 5WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656. 被引量:1
  • 6WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8. 被引量:1
  • 7BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275. 被引量:1
  • 8BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5. 被引量:1
  • 9ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2. 被引量:1
  • 10SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512. 被引量:1

共引文献421

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部